This technology is a cell-based therapy involving an administered dose of cells expressing both CD14+ and CD64+ ligands. It is designed to promote healing in diabetic patients, with potential to reduce inflammation and support tissue regeneration. The cells can be observed in tissue, blood, and bone marrow, allowing for broader variety in addressing systemic diabetic complications. Background: Chronic inflammation is a hallmark of diabetes, driven by factors such as insulin resistance, elevated blood glucose levels, and the accumulation of advanced glycation end products (AGEs). In diabetic patients, this persistent low-grade inflammation impairs immune function and hinders wound healing. Current treatments often fail to effectively modulate this dysregulated inflammatory response. This technology aims to restore immune balance and promote recovery by leveraging cells that express both CD64+ and CD14+ ligands. Applications:
Advantages: